Raymond James Financial Services Advisors’s ImmunityBio IBRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$79.2K	Buy	21,301 +4,300	+25%	+$19.9K	﹤0.01%	3323
2024 Q2	$107K	Buy	17,001 +1,600	+10%	+$10.5K	﹤0.01%	3222
2024 Q1	$82.7K	Buy	15,401 +3,195	+26%	+$14.5K	﹤0.01%	3247
2023 Q4	$61.3K	Buy	12,206 +250	+2%	+$784	﹤0.01%	3184
2023 Q3	$20.2K	Sell	11,956 -850	-7%	-$1.71K	﹤0.01%	3192
2023 Q2	$35.6K	Sell	12,806 -1,108	-8%	-$3.13K	﹤0.01%	3151
2023 Q1	$25.3K	Buy	13,914 +900	+7%	+$2.8K	﹤0.01%	3166
2022 Q4	$66K	Sell	13,014 -1,500	-10%	-$8.24K	﹤0.01%	3060
2022 Q3	$72K	Buy	14,514 +893	+7%	+$4.07K	﹤0.01%	3046
2022 Q2	$51K	Buy	+13,621	New	+$54.7K	﹤0.01%	3088

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial Services Advisors's IBRX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its ImmunityBio (IBRX) stake by 25% in Q3 2024, buying an estimated $19.9K and bringing the position to 21,301 shares worth $79.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3323.

Raymond James Financial Services Advisors first reported a position in IBRX in Q2 2022 and has held it in 10 quarters since. The position peaked at $107K in Q2 2024. 182 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

Raymond James Financial Services Advisors held 21,301 shares of ImmunityBio worth $79.2K as of Q3 2024.
Raymond James Financial Services Advisors bought 4,300 ImmunityBio shares in Q3 2024, an estimated $19.9K.
ImmunityBio made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3323 holding.
Raymond James Financial Services Advisors first reported a position in ImmunityBio in Q2 2022 and has held it in 10 quarters since.
Raymond James Financial Services Advisors's ImmunityBio position peaked at $107K in Q2 2024.
182 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.